Tumor Models Archives - WuXi Biology

PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 – 25%...

Radionuclide Drug Conjugates in Anticancer Treatment

Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...

DLL3‑related Tumor Models in Humanized Mice

OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as well...

Spontaneous Mouse Tumor-derived Syngeneic Models

Spontaneous mouse tumor-derived syngeneic models are valuable tools in preclinical cancer research. These tumor models offer unique advantages because immunotherapies...

PBMC Humanized Tumor Models for Evaluating T-cell Engagers

T-cell engagers (TCEs) are a class of bispecific antibody-based immunotherapies designed to bring T cells into close proximity with cancer...

ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...

Knowledge Library